Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients

Phase 1

• Conditions: Stroke; Umbilical Cord Blood; Erythropoietin; Safety; Treatment Outcome
• Interventions: Drug: Placebo umbilical cord blood infusion; Drug: Umbilical cord blood infusion; Drug: Erythropoietin injection; Drug: Placebo erythropoietin injection; Procedure: Active rehabilitation

• Registration Number: NCT04013646
• Lead Sponsor: Bundang CHA Hospital

Brief Summary

This clinical trial is a clinical trial for the evaluation of the safety and efficacy of umbilical cord blood (UCB) therapy, UCB and erythropoietin (EPO) combination therapy in adult stroke patients.

Detailed Description

UCB is a high-quality source of mesenchymal stem cells, and studies are being actively developed for stroke patients. UCB therapy has a neuroprotective effect through anti-inflammatory effect and anti-apoptosis.

However, UCB alone has not been able to provide sufficient improvement and is being studied for combination therapies with growth factors that can exert its effects. Among the various growth factors, EPO is a powerful factor that can act as a neurotrophic factor in neurons, astrocytes, oligodendrocytes, microglia, endothelial cells, and neural stem/precursor cells.

In our previous study of subacute stroke animal models, investigators confirmed that the combined administration of UCB and EPO improved the behavioral assessment (mNSS, Cylinder test) compared to UCB only administration.

The aim of this study is to investigate the difference in therapeutic effects between UCB alone therapy and UCB and EPO combination therapy.

Study Timeline

• Study Start: 2019-05-02
• Study First Submitted: 2019-07-08
• Study First Submitted QC: 2019-07-08
• Study First Posted: 2019-07-10
• Status Verified: 2020-11
• Primary Completion: 2020-11-02
• Last Update Submitted: 2020-11-03
• Last Update Posted: 2020-11-05
• Study Completion: 2021-11-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Adult patients over 20 years old
2. Patients with a stroke lasting from 30 days to less than 9 months
3. After hearing and fully understanding the details of this clinical trial, the person or legal representative has agreed to voluntary participation and has agreed in writing to comply with the notice

Exclusion Criteria

Patients with one or more of the following can not participate in the study.

1. Patients with uncontrolled hypertension

2. A person who has impaired ability of consent, who is not accompanied by a guardian

3. Women who are pregnant, lactating, have a pregnancy plan during the trial, or those who do not use an available contraceptive method (women of childbearing age must be negative in the pregnancy test on baseline visit (0 weeks) .)

4. Those who satisfy the following conditions

   • A person whose ALT / AST is measured at 120 IU / L or more
   • Serum creatinine greater than 1.8 mg / dL
   • Total bilirubin> 1.8 mg / dL
   • Total WBC count less than 3000 / mm3
   • Those with a Hb of 16 g / dL or more
   • Platelet count less than 150,000 / uL or more than 675,000 / uL

5. Clinically significant infections during the screening period (pneumonia, pyelonephritis, sepsis, etc.)

6. Persons with severe medical conditions such as cardiovascular, digestive, respiratory, and endocrine conditions.

7. Any kind of confirmed congenital or acquired immune deficiency syndrome

8. Those who have been diagnosed with malignant carcinoma (excluding complete remission for more than 10 years)

9. If participants have side effects on your medication [Regarding erythropoietin agent]

   • Patients with hypersensitivity to erythropoietin
   • Patients sensitive to mammalian cell-derived drugs or human albumin
   • epileptic patients
   • Patients with a history of seizures
   • Patients on a thrombolytic drug (meaning thrombolytic agent such as Tissue Plasminogen Activator, allowing anti-platelet agents such as aspirin and plavix) [Related to tacrolimus] Patients with hypersensitivity to tacrolimus or macrolide compounds
   • Patients receiving cyclosporine or bosentan
   • Patients receiving potassium-preserving diuretics

10. Other If the investigator determines that participation in this trial is not appropriate

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo UCB infusion and placebo EPO injection group	Erythropoietin injection	Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
UCB infusion and EPO injection group	Placebo umbilical cord blood infusion	Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
UCB infusion and EPO injection group	Placebo erythropoietin injection	Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
UCB infusion and EPO injection group	Active rehabilitation	Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin agent injects into the peripheral vein 5 times a total of 5 times a week.
UCB infusion and placebo EPO injection group	Umbilical cord blood infusion	Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.
UCB infusion and placebo EPO injection group	Active rehabilitation	Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.
Placebo UCB infusion and placebo EPO injection group	Umbilical cord blood infusion	Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
Placebo UCB infusion and placebo EPO injection group	Active rehabilitation	Take immunosuppressant placebo for 1 week with the same schedule as the experimental group. As in the experimental group, placebo umbilical cord blood is administered in the treatment room and stay in the treatment room for the same time. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week. Other inspection schedules proceed with other groups.
UCB infusion and placebo EPO injection group	Placebo erythropoietin injection	Take immunosuppressant agents for 1 week. Umbilical cord blood is administered in the treatment room. Afterward, the venous erythropoietin placebo injects into the peripheral vein 5 times a total of 5 times a week.

Primary Outcome Measures

Name	Time	Method
Change of Functional Independence Measure	baseline - 3 months - 6 months	The difference in the FIM (Functional Independence Measure)score between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences in scores (total score\[18\~126\], motor score\[13\~90\], and cognition score\[5\~35\]. The total score is the sum of the motor score and the cognition score. The higher scores represent a better outcome )

Secondary Outcome Measures

Name	Time	Method
Change of Manual Function Test	baseline - 3 months - 6 months	The difference in the MFT (Manual Function Test) between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences.\[0\~32 for each arm\] (The higher values represent a better outcome.)
Change of Fugl-Meyer Assessment	baseline - 3 months - 6 months	The difference in the FMA (Fugl-Meyer Assessment) between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences.\[0\~66 for each arm\] (The higher values represent a better outcome.)
Change of Berg Balance Scale	baseline - 3 months - 6 months	The difference in the BBS (Berg Balance Scale) between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences.\[0\~56\] (The higher values represent a better outcome.)
Change of Trunk Imbalance Scale	baseline - 3 months - 6 months	The difference in the TIS (Trunk Imbalance Scale) between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences.\[0\~23\] (The higher values represent a better outcome.)
Change of Medical research council	baseline - 3 months - 6 months	The difference in the MRC (Medical research council) scale between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences. \[0, 1, 2, 2, 2+, 3-, 3, 3+, 4, 5\] (The higher values represent a better outcome.)
Change of National Institutes of Health Stroke Scale	baseline - 3 months - 6 months	The difference in the NIHSS (National Institutes of Health Stroke Scale) between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences.\[0\~42\] (The lower values represent a better outcome.)
Change of Korean Mini Mental State Exam	baseline - 3 months - 6 months	The difference in the K-MMSE (Korean Mini Mental State Exam) between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences. \[0\~30\] (The higher values represent a better outcome.)
Change of Korean Wechsler adult intelligence scale-IV	baseline - 3 months - 6 months	The difference in the K-WAIS-IV (Korean Wechsler adult intelligence scale-IV) between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences.\[The total score is a standard score with a mean of 100 and a standard deviation of approximately 15.\] (The higher values represent a better outcome.)
Change of Korean version of the Western Aphasia Battery	baseline - 3 months - 6 months	The difference in the K-WAB (Korean version of the Western Aphasia Battery) between the three groups at baseline, 90 days, and 180 days was confirmed by comparing differences.\[0\~100\] (The higher values represent a better outcome.)
Change of Brain imaging	baseline - 6 months	The difference in the Brain imaging (Basic brain MRI, functional brain MRI, diffusion tensor imaging brain MRI) between the three groups at baseline, and 180 days was confirmed by comparing differences.
Change of Biomarkers	baseline - 1 day - 15 days - 1 month - 3 months - 6 months	The difference in the Biomarkers (TGFβ, IL-10, IL-8, PTX3, PCNT,...) between the three groups at baseline, 1 day, 15 days, 30 days, 90 days and 180 days was confirmed by comparing differences.

Trial Locations

Locations (1)

Bundang CHA Medical Center; 🇰🇷 Seongnam-si, Gyeonggi-do, Korea, Republic of